Engelman et al. [12] constructed lung cancer cell lines resistant to Erlotinib and found that MET amplification was detected in about 22% of the samples, suggesting that MET amplification may be one of the important factors leading to Erlotinib resistance in lung cancer cell lines. Here, MET is linked to lung carcinoma.